NASDAQ:BIOR Biora Therapeutics (BIOR) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free BIOR Stock Alerts $1.10 -0.07 (-5.98%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1750-Day Range$0.81▼$1.5452-Week Range$0.76▼$6.70Volume353,649 shsAverage Volume385,770 shsMarket Capitalization$29.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biora Therapeutics alerts: Email Address Biora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.06) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.83 out of 5 starsMedical Sector852nd out of 938 stocksPharmaceutical Preparations Industry384th out of 422 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Biora Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.82% of the float of Biora Therapeutics has been sold short.Short Interest Ratio / Days to CoverBiora Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biora Therapeutics has recently increased by 4.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiora Therapeutics does not currently pay a dividend.Dividend GrowthBiora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOR. Previous Next 3.0 News and Social Media Coverage News SentimentBiora Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.Search Interest18 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows5 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.18% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.74% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biora Therapeutics are expected to grow in the coming year, from ($2.06) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biora Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Biora Therapeutics Stock (NASDAQ:BIOR)Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Read More BIOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOR Stock News HeadlinesMarch 28, 2024 | seekingalpha.comBiora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBIOR: Negotiations AcceleratingMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 27, 2024 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 27, 2024 | benzinga.comBiora Therapeutics: Q4 Earnings InsightsMarch 27, 2024 | finance.yahoo.comQ4 2023 Biora Therapeutics Inc Earnings CallMarch 26, 2024 | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 25, 2024 | markets.businessinsider.comHere's what Wall Street expects from Biora Therapeutics's earningsMarch 24, 2024 | americanbankingnews.comBiora Therapeutics (BIOR) Scheduled to Post Earnings on TuesdayMarch 18, 2024 | globenewswire.comBiora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateMarch 11, 2024 | msn.comBiora Therapeutics announces new capital investmentMarch 11, 2024 | globenewswire.comBiora Therapeutics Further Reduces Net Debt and Monetizes Legacy AssetMarch 7, 2024 | finance.yahoo.comBIOR Jul 2024 4.000 callMarch 7, 2024 | finance.yahoo.comBIOR Apr 2024 2.500 putMarch 7, 2024 | finance.yahoo.comBIOR Apr 2024 1.000 putMarch 7, 2024 | finance.yahoo.comBIOR Oct 2024 2.000 callMarch 3, 2024 | ca.finance.yahoo.comBIOR Oct 2024 4.000 putMarch 1, 2024 | morningstar.comBiora Therapeutics Inc Ordinary Shares BIORFebruary 26, 2024 | finance.yahoo.comBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600February 26, 2024 | globenewswire.comBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600February 21, 2024 | markets.businessinsider.comHere's what Wall Street expects from iRhythm Technologies's earnings reportFebruary 17, 2024 | finance.yahoo.comBIOR Mar 2024 1.000 callFebruary 8, 2024 | finance.yahoo.comBiora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease SymposiumJanuary 22, 2024 | finance.yahoo.comBiora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.January 8, 2024 | finance.yahoo.comBiora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600See More Headlines Receive BIOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOR CUSIPN/A CIK1580063 Webwww.bioratherapeutics.com Phone833-727-2841FaxN/AEmployees54Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,160,000.00 Net Margins-55,269.39% Pretax Margin-677,261.06% Return on EquityN/A Return on Assets-135.62% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($11.46) per share Price / Book-0.10Miscellaneous Outstanding Shares27,210,000Free Float20,902,000Market Cap$30.07 million OptionableOptionable Beta1.11 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Aditya P. Mohanty M.B.A. (Age 57)CEO & Director Comp: $858.82kMr. Eric d'Esparbes (Age 56)Executive VP & CFO Comp: $651.91kMr. Clarke Neumann J.D. (Age 60)Senior VP, General Counsel & Secretary Comp: $624.13kEric FoxVP of Finance & Accounting & TreasurerMr. Troy Seelye (Age 60)Chief Information Officer Mr. George Gianakopoulos (Age 63)Senior Vice President of Sales Ms. Robyn HattonHead of Human ResourcesMr. Kevin Howe Ph.D.Senior VP of Strategic OperationsDr. Sharat Singh Ph.D. (Age 65)Head of Research Dr. Paul Shabram M.B.A.Head of Technical OperationsMore ExecutivesKey CompetitorsProMIS NeurosciencesNASDAQ:PMNDURECTNASDAQ:DRRXTheratechnologiesNASDAQ:THTXSELLAS Life Sciences GroupNASDAQ:SLSMarker TherapeuticsNASDAQ:MRKRView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 229,183 shares on 3/11/2024Ownership: 1.867%Virtu Financial LLCBought 19,763 shares on 2/26/2024Ownership: 0.073%Vanguard Group Inc.Bought 229,183 shares on 2/15/2024Ownership: 1.867%View All Institutional Transactions BIOR Stock Analysis - Frequently Asked Questions Should I buy or sell Biora Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks. How have BIOR shares performed in 2024? Biora Therapeutics' stock was trading at $1.35 at the start of the year. Since then, BIOR stock has decreased by 18.5% and is now trading at $1.10. View the best growth stocks for 2024 here. When is Biora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BIOR earnings forecast. How were Biora Therapeutics' earnings last quarter? Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.01. The company earned $0.18 million during the quarter, compared to analyst estimates of $11.10 million. During the same period in the prior year, the company posted ($1.01) EPS. When did Biora Therapeutics' stock split? Shares of Biora Therapeutics reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Biora Therapeutics' major shareholders? Biora Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.87%), Vanguard Group Inc. (1.87%), Virtu Financial LLC (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L and Surbhi Sarna. View institutional ownership trends. How do I buy shares of Biora Therapeutics? Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.